» Articles » PMID: 22266706

Downregulation of Mcl-1 Synergizes the Apoptotic Response to Combined Treatment with Cisplatin and a Novel Fiber Chimeric Oncolytic Adenovirus

Overview
Journal Oncol Rep
Specialty Oncology
Date 2012 Jan 24
PMID 22266706
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of this study was to examine the effects of SG511, a novel fiber chimeric oncolytic adenovirus with E1B 55-kDa deleted, combined with cisplatin on cancer cells and to identify their underlying mechanisms. The combined effect of SG511 and cisplatin on HeLa and HT-29 cells was assessed by a crystal violet assay and an MTT assay, followed by combination index analysis. Cell apoptosis was evaluated by DAPI staining and visualized by fluorescein-mediated signal detection. Mitochondrial membrane potential was detected by flow cytometric analysis of Rhodamine 123 accumulation. The activation of the caspase pathway and the expression of Bcl-2 family proteins were examined by western blotting. Results show that SG511 vector infected various human cancer cell lines and induced growth inhibition effectively. Of note, SG511 synergistically enhanced the anti-proliferative activity of cisplatin, a DNA-damaging agent, against HeLa and HT-29 cells in vitro, concomitantly with increased apoptosis and activation of the mitochondrial pathway. Furthermore, treatment with SG511 alone or in combination with cisplatin resulted in reduced expression the anti-apoptotic Bcl-2 family member Mcl-1 in HeLa and HT-29 cells. Importantly, this combination did not increase the growth inhibitory effects of cisplatin on human normal liver cells. Collectively, SG511, a novel fiber chimeric oncolytic adenovirus, sensitizes cancer cells to apoptosis by reducing anti-apoptotic Mcl-1 protein levels.

Citing Articles

Combining Oncolytic Viruses and Small Molecule Therapeutics: Mutual Benefits.

Spiesschaert B, Angerer K, Park J, Wollmann G Cancers (Basel). 2021; 13(14).

PMID: 34298601 PMC: 8306439. DOI: 10.3390/cancers13143386.


Oncolytic virotherapy promotes radiosensitivity in soft tissue sarcoma by suppressing anti-apoptotic MCL1 expression.

Omori T, Tazawa H, Yamakawa Y, Osaki S, Hasei J, Sugiu K PLoS One. 2021; 16(4):e0250643.

PMID: 33886686 PMC: 8061981. DOI: 10.1371/journal.pone.0250643.


Inhibition of Kpnβ1 mediated nuclear import enhances cisplatin chemosensitivity in cervical cancer.

Chi R, van der Watt P, Wei W, Birrer M, Leaner V BMC Cancer. 2021; 21(1):106.

PMID: 33530952 PMC: 7852134. DOI: 10.1186/s12885-021-07819-3.


Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction.

Yamakawa Y, Tazawa H, Hasei J, Osaki S, Omori T, Sugiu K Cancer Sci. 2017; 108(9):1870-1880.

PMID: 28685948 PMC: 5581539. DOI: 10.1111/cas.13316.


Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances.

Simpson G, Relph K, Harrington K, Melcher A, Pandha H Oncolytic Virother. 2016; 5:1-13.

PMID: 27579292 PMC: 4996257. DOI: 10.2147/OV.S66083.


References
1.
Fukuda K, Abei M, Ugai H, Kawashima R, Seo E, Wakayama M . E1A, E1B double-restricted replicative adenovirus at low dose greatly augments tumor-specific suicide gene therapy for gallbladder cancer. Cancer Gene Ther. 2008; 16(2):126-36. DOI: 10.1038/cgt.2008.67. View

2.
Go R, Adjei A . Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 1999; 17(1):409-22. DOI: 10.1200/JCO.1999.17.1.409. View

3.
Baird S, Aerts J, Eddaoudi A, Lockley M, Lemoine N, McNeish I . Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer. Oncogene. 2007; 27(22):3081-90. PMC: 2493060. DOI: 10.1038/sj.onc.1210977. View

4.
Conrad C, Miller C, Ji Y, Gomez-Manzano C, Bharara S, McMurray J . Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization. Cancer Gene Ther. 2005; 12(3):284-94. DOI: 10.1038/sj.cgt.7700750. View

5.
Wang G, Li G, Liu H, Yang C, Yang X, Jin J . E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies. J Gene Med. 2009; 11(6):477-85. DOI: 10.1002/jgm.1326. View